This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
CARD Trial
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Advanced Bladder Cancer
JAVELIN Bladder 100 Trial
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
Urologic Oncology
Prostate Cancer
nmCRPC
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2022
ASCO 2022
Upcoming
EAU 2022
See All
See All Conference Coverage
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)
April 23, 2014
EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials
April 16, 2014
EAU 2014 - Poster: Greater short-term relief of lower urinary tract symptoms in prostate cancer patients treated with degarelix compared to goserelin plus bicalutamide: Results of a pooled analysis
April 16, 2014
EAU 2014 - Poster: Consistent long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: Final results of repeated treatments up to 4 years
April 16, 2014
EAU 2014 - Poster: OnabotulinumtoxinA reduces urinary incontinence and improves quality of life in overactive bladder patients regardless of use of clean intermittent catheterisation or the presence of urinary tract infection
April 16, 2014
EAU 2014 - Poster: An economic model to investigate differences in resource utilisation associated with the use of BOTOX® to manage urinary incontinence in patients with idiopathic overactive bladder in the United Kingdom
April 16, 2014
EAU 2014 - Poster: Consistent improvements in urinary urgency following repeat onabotulinumtoxinA treatments in patients with overactive bladder syndrome and urinary incontinence
April 16, 2014
EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy
April 16, 2014
EAU 2014 - Poster: Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial
April 16, 2014
EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial
April 16, 2014
EAU 2014 - Poster: A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses
April 15, 2014
EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials
April 15, 2014
EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
April 15, 2014
EAU 2014 - Nephron sparing surgery does not decrease other-causes mortality relative to radical nephrectomy in patients with clinical T1a-T1b renal mass: Results from a large multi-institutional study - Session Highlights
April 15, 2014
EAU 2014 - A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses - Session Highlights
April 15, 2014
EAU 2014 - Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation - Session Highlights
April 15, 2014
EAU 2014 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights
April 15, 2014
EAU 2014 - Long-term immunotherapy by dendritic-cells based vaccine in patients with PSA-recurrent prostate cancer - Session Highlights
April 15, 2014
EAU 2014 - Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid - Session Highlights
April 15, 2014
EAU 2014 - Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials - Session Highlights
April 15, 2014
Page 420 of 472
Start
Prev
415
416
417
418
419
420
421
422
423
424
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free